ACE and Cachexia: The highly lipophilic ACE inhibitor imidapril (VitorTM) (30 mg kg−1) attenuated the development of weight loss in mice bearing the MAC16 tumour, suggesting that Ang II may play a role in the development of cachexia in this model.